PGE2-Driven Induction and Maintenance of Cancer-Associated Myeloid-Derived Suppressor Cells
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Myeloid-derived suppressor cells (MDSCs) are critical mediators of tumor-associated immune suppression, with their numbers and activity strongly increased in most human cancers and animal models. MDSCs suppress anti-tumor immunity through multiple mechanisms, including the manipulation of arginine and tryptophan metabolism by such factors as arginase (Arg), inducible nitric oxide synthase (iNOS/NOS2), and indoleamine-2,3-dioxygenase (IDO). Prostaglandin E(2) (PGE(2)), a mediator of chronic inflammation and tumor progression, has emerged as a key molecule in MDSC biology. PGE(2) promotes MDSC development and their induction by additional factors, directly suppresses T cell immune responses and participates in the induction of other MDSC-associated suppressive factors, including Arg, iNOS and IDO. It further promotes MDSC recruitment to tumor environments through the local induction of CXCL12/SDF-1 and the induction and stabilization of the CXCL12 receptor, CXCR4, on tumor-associated MDSCs. The establishment of a positive feedback loop between PGE(2) and cyclooxygenase 2 (COX-2), the key regulator of PGE(2) synthesis, stabilizes the MDSC phenotype and is required for their suppressive function. The central role of PGE(2) in MDSC biology provides for a feasible target for counteracting MDSC-mediated immune suppression in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“Hypoxia-inducible factor 1 (HIF-1) and HIF-2 have also been implicated in the induction of both Arg1 and iNOS in MDSCs (Rodriguez and Ochoa, 2008; Semenza, 2003).”
BackgroundHypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 2×
“Tumor environment-associated hypoxia has also been proposed as a regulator of MDSC development and function (Harris, 2002), with the downstream transcription factor HIF-1α mediating the induction of MDSC immunosuppressive factors and the suppression of antigen-non-specific T cell functions (Carmeliet et al.”
BackgroundNitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502 · cited 2×
“…regulator of MDSC development and function (Harris, 2002), with the downstream transcription factor HIF-1α mediating the induction of MDSC immunosuppressive factors and the suppression of antigen-non-specific T cell functions (Carmeliet et al., 1998; Corzo et al., 2010; Rodriguez and Ochoa, 2008).”
BackgroundIdo expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341 · cited 2×
“…is further enhanced by the endogenous activity of such enzymes as arginase 1 (Arg1) (Bronte and Zanovello, 2005; Ochoa et al., 2007), inducible nitric oxide synthase (iNOS, NOS2) (Bronte and Zanovello, 2005), and indoleamine 2,3-dioxygenase 1 (IDO1) (Hwu et al., 2000; Mellor and Munn, 2004).”
BackgroundUyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 1×
“IDO1 catalyzes the initial and rate-limiting step in the degradation of tryptophan via the kynurenine pathway, and constitutes an important mechanism of immune dysfunction in cancer (Munn and Mellor, 2007; Prendergast, 2008; Uyttenhove et al., 2003).”
BackgroundRegulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775 · cited 8×
“…et al., 2009), as well as activated granulocytic MDSCs (Rodriguez et al., 2009; Schmielau and Finn, 2001) expressing high levels of CD66b, CD11b, and VEGFR1 and low levels of CD62L and CD16 (Rodriguez et al., 2009), Arg1, and/or iNOS (Bronte and Zanovello, 2005; Gabrilovich and Nagaraj, 2009).”
BackgroundInfluentialThe role of myeloid cells in the promotion of tumour angiogenesis
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642 · cited 2×
“…et al., 2005), MDSCs further promote tumor progression through the expansion of regulatory T cells (Tregs) (Huang et al., 2006; Serafini et al., 2008), suppression of macrophage functions (Sinha et al., 2007a), and regulation of tumor angiogenesis (Murdoch et al., 2008; Yang et al., 2004).”
BackgroundHuang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435 · cited 11×
“PGE2 has also been shown to directly induce FoxP3 þ T cells with immunoregulatory properties (Baratelli et al., 2005; Sharma et al., 2005a), a suppressive mechanism often employed by MDSCs (Hoechst et al., 2008; Huang et al., 2006; Yang et al., 2006).”
BackgroundInfluentialBlockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · cited 2×
“MDSCs have also been shown to utilize cell-surface molecules (Curiel et al., 2003; Liu et al., 2008; Pan et al., 2010; Yang et al., 2006), TGF-β (Filipazzi et al.”
BackgroundRodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0465 · Cited by 1,276 · cited 4×
“The co-expression and combined activity of both enzymes in MDSCs has been associated with their suppression of CD8þ T cells (Kusmartsev and Gabrilovich, 2005; Rodriguez et al., 2004; Sinha et al., 2005; Van Ginderachter et al., 2006).”
BackgroundInfluentialCorzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173
Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., & Lin, P. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.031 · Cited by 1,140 · cited 2×
“…et al., 2005), MDSCs further promote tumor progression through the expansion of regulatory T cells (Tregs) (Huang et al., 2006; Serafini et al., 2008), suppression of macrophage functions (Sinha et al., 2007a), and regulation of tumor angiogenesis (Murdoch et al., 2008; Yang et al., 2004).”
BackgroundGabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048
Sinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M., & Ostrand-Rosenberg, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.977 · Cited by 847 · cited 9×
“Several studies also indicate the involvement of the EP2 and EP4 receptors, but not the EP1 and EP3 receptors, in mediating the MDSC-promoting effects of PGE2 (Obermajer et al., 2011a; Rodriguez et al., 2005; Sinha et al., 2007b).”
BackgroundInfluentialHoechst, B., Ormandy, L. A., Ballmaier, M., Lehner, F., Krüger, C., Manns, M. P., Greten, T. F., & Korangy, F. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.020 · Cited by 793 · cited 4×
“These include CD14þCD11bþHLA-DRlow monocytic MDSCs (Filipazzi et al., 2007; Hoechst et al., 2008; Hoechst et al., 2009; Mundy-Bosse et al., 2011; Raychaudhuri et al., 2011; Vuk-Pavlovic et al., 2010) and CD15þ neutrophil-related immature (i)MDSCs (Corzo et al., 2009), as well as activated…”
BackgroundInfluentialMenetrier-Caux, C., Montmain, G., Dieu, M. C., Bain, C., Favrot, M. C., Caux, C., & Blay, J. Y. (1998) · Blood · doi:10.1182/blood.v92.12.4778 · Cited by 590 · cited 3×
“These include CD14þCD11bþHLA-DRlow monocytic MDSCs (Filipazzi et al., 2007; Hoechst et al., 2008; Hoechst et al., 2009; Mundy-Bosse et al., 2011; Raychaudhuri et al., 2011; Vuk-Pavlovic et al., 2010) and CD15þ neutrophil-related immature (i)MDSCs (Corzo et al., 2009), as well as activated granulocytic MDSCs (Rodriguez…”
BackgroundHyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer
Nefedova, Y., Huang, M., Kusmartsev, S., Bhattacharya, R., Cheng, P., Salup, R., Jove, R., & Gabrilovich, D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.464 · Cited by 464 · cited 1×
“Most of these factors signal via signal transducer and activator of transcription 3 (Stat3), arguably the main transcription factor regulating the expansion of MDSCs (Kortylewski et al., 2005; Nefedova et al., 2004; Nefedova et al., 2005).”
BackgroundInducible Nitric-oxide Synthase Generates Superoxide from the Reductase Domain
Xia, Y., Roman, L. J., Masters, B. S. S., & Zweier, J. L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.35.22635 · Cited by 388 · cited 1×
“In addition, at low concentrations of L-arginine, Arg1 collaborates with iNOS (Bronte et al., 2003) in the generation of suppressive reactive nitrogen oxygen species (RNOS, i.e., reactive nitrogen intermediates, RNI) and ROS (H2O2) (Xia et al., 1998; Xia and Zweier, 1997).”
Background
Cited by
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Navigating metabolic pathways to enhance antitumour immunity and immunotherapy
Li, X., Wenes, M., Romero, P., Huang, S. C.-C., Fendt, S.-M., & Ho, P.-C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0203-7 · Cited by 733
Shaping Polarization Of Tumor-Associated Macrophages In Cancer Immunotherapy
Gao, J., Liang, Y., & Wang, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.888713 · Cited by 555
The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment
Sionov, R. V., Fridlender, Z. G., & Granot, Z. (2015) · Cancer Microenvironment · doi:10.1007/s12307-014-0147-5 · Cited by 416
Li, L., Yu, R., Cai, T., Chen, Z., Lan, M., Zou, T., Wang, B., Wang, Q., Zhao, Y., & Cai, Y. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106939 · Cited by 381
Metadata
- Authors
- Obermajer, N., Wong, J. L., Edwards, R. P., Odunsi, K., Moysich, K., & Kalinski, P.
- Venue
- Immunological Investigations
- Publisher
- Informa UK Limited
- Published
- 2012-08
- Volume
- 41
- Issue
- 6-7
- Pages
- 635-657
- ISSN
- 0882-0139 (ISSN-L)
- 1532-4311
- OpenAlex
- W2165239729
- Cited by
- 144
- References
- 20
- FWCI
- 4.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.